OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B

Miles Wang, a prominent researcher formerly with OpenAI, is set to embark on an ambitious venture focused on harnessing artificial intelligence to revolutionize drug discovery. His departure from the renowned AI organization comes as he prepares to establish a startup dedicated to developing advanced AI models aimed at enhancing the pharmaceutical development process. Sources indicate that Wang is currently negotiating to secure approximately $200 million in funding, with the startup's valuation projected at around $2 billion. Notably, Lightspeed Venture Partners is reportedly in talks to spearhead this funding round. However, details regarding the deal remain fluid, and both Wang and Lightspeed have not confirmed specifics publicly. The growing interest from investors in applying AI to the life sciences sector reflects a broader trend, especially as other startups in this arena have recently achieved significant funding milestones. For instance, Chai Discovery, an innovative company specializing in AI-driven predictions of molecular interactions for drug identification, has just announced a $400 million raise at a valuation of $3.8 billion. Similarly, Isomorphic Labs, a spinout from Google DeepMind, completed a substantial $2.1 billion Series B funding round earlier this year. Wang's upcoming startup may focus on utilizing AI to uncover new applications for existing medications, including those that previously did not succeed in clinical trials. This approach could lead to expedited revenue generation, as these drugs have already undergone safety evaluations by the FDA. Having joined OpenAI in 2024 after leaving Harvard, where he pursued a degree in computer science, Wang contributed significantly to research on how AI can streamline scientific discovery. His move to create a startup signals a renewed confidence among investors in backing young entrepreneurs, even those without completed degrees, in the tech landscape.